-
公开(公告)号：US20150099302A1
公开(公告)日：2015-04-09
申请号：US14571425
申请日：2014-12-16
Inventor： Ugur Sahin , Ozlem Tureci , Torsten Seppmann , Holger Hoff , Jens Schumacher
IPC: C07K14/705 , C12N5/0781 , C07K16/00
CPC classification number: C07K14/70578 , C07K16/00 , C07K2319/30 , C12N5/0635
Abstract: The present invention provides recombinant proteins comprising the amino acid sequence of an intracellular segment of CD40 and an amino acid sequence mediating the association of the recombinant protein with the constant region of an immunoglobulin heavy chain. The recombinant proteins according to the present invention are useful for inducing clonal expansion of a B cell having a predetermined antigen-specificity without the need for T cell or CD40L mediated co-stimulation. Thus, the present invention provides tools for clonal expansion of B cells specific for an antigen of interest and the production of B cells secreting antibodies specific for an antigen of interest. The recombinant proteins of the present invention may also be used for generating fully human monoclonal antibodies with a predetermined antigen-specificity from the B cell repertoire of a human subject.
Abstract translation: 本发明提供重组蛋白，其包含CD40的细胞内节段的氨基酸序列和介导重组蛋白与免疫球蛋白重链的恒定区的缔合的氨基酸序列。 根据本发明的重组蛋白质可用于诱导具有预定抗原特异性的B细胞的克隆扩增，而不需要T细胞或CD40L介导的共刺激。 因此，本发明提供了用于针对感兴趣的抗原特异性的B细胞的克隆扩增的工具，以及产生分泌针对感兴趣的抗原的抗体的B细胞。 本发明的重组蛋白还可用于从人受试者的B细胞库中产生具有预定抗原特异性的完全人单克隆抗体。
-
公开(公告)号：US20150086612A1
公开(公告)日：2015-03-26
申请号：US14388192
申请日：2013-03-25
Applicant: BioNTech AG , TRON - Translationale Onkologie an der Johannes Gutenberg-Universität Mainz Gemeinnützge GmbH , Universitätsmedizin der Johannes Gutenber-Universität Mains
Inventor： Ugur Sahin , Heinrich Haas , Sebastian Kreiter , Mustafa Diken , Daniel Fritz , Martin Meng , Lena Mareen Kranz , Kerstin Reuter
Abstract: The present invention is in the field of immunotherapy, in particular tumor immunotherapy. The present invention provides pharmaceutical formulations for delivering RNA to antigen presenting cells such as dendrite cells (DCs) in the spleen after systemic administration. In particular, the formulations described herein enable to induce an immune response after systemic administration of antigen-coding RNA.
Abstract translation: 本发明涉及免疫治疗领域，特别是肿瘤免疫治疗领域。 本发明提供用于在全身给药后将脾脏中的抗原提呈细胞例如树突状细胞（DC）递送RNA的药物制剂。 特别地，本文描述的制剂能够在全身给予抗原编码RNA之后诱导免疫应答。
-
公开(公告)号：US20140134201A1
公开(公告)日：2014-05-15
申请号：US14152597
申请日：2014-01-10
Applicant: BioNTech AG
Inventor： Ozlem Tureci , Ugur Sahin , Sebastian Kreiter
IPC: A61K47/48
CPC classification number: A61K47/64 , A61K48/00 , C07K14/4748 , C07K14/70539 , C07K2319/02 , C07K2319/03
Abstract: The present invention relates to fusion molecules of antigens, the nucleic acids coding therefor and the use of such fusion molecules and nucleic acids. In particular, said invention relates to fusion molecules, comprising an antigen and the trans-membrane region and cytoplasmic region of a MHC molecule and/or the cytoplasmic region of a MHC or a SNARE molecule.
Abstract translation: 本发明涉及抗原的融合分子，其编码的核酸以及这种融合分子和核酸的使用。 特别地，本发明涉及融合分子，其包含MHC或SNARE分子的MHC分子和/或细胞质区域的抗原和跨膜区域和胞质区域。
-
64.发明申请IDENTIFICATION OF SURFACE-ASSOCIATED ANTIGENS FOR TUMOR DIAGNOSIS AND THERAPY 有权用于肿瘤诊断和治疗的表面相关抗原的鉴定公开(公告)号：US20140017679A1
公开(公告)日：2014-01-16
申请号：US13864411
申请日：2013-04-17
Applicant: BioNTech AG
Inventor： Ugur Sahin , Ozlem Tureci , Michael Koslowski , Gerd Helftenbein , Dirk Usener , Volker Schluter
IPC: C12Q1/68
CPC classification number: G01N33/57492 , C12Q1/6886 , C12Q2600/118 , C12Q2600/158 , G06F19/22
Abstract: The invention relates to identifying tumor-associated genetic products and encoding nucleic acids thereof. A therapy and diagnosis of diseases in which the tumor-associated genetic products are aberrantly expressed, proteins, polypeptides and peptides which are expressed in association with tumor and the encoding nucleic acids for said proteins, polypeptides and peptides are also disclosed.
Abstract translation: 本发明涉及鉴定肿瘤相关基因产物并编码其核酸。 还公开了与肿瘤相关表达的肿瘤相关遗传产物异常表达的疾病的治疗和诊断，以及用于所述蛋白质，多肽和肽的编码核酸的蛋白质，多肽和肽。
-
公开(公告)号：US11787862B2
公开(公告)日：2023-10-17
申请号：US16335373
申请日：2017-09-20
Applicant: BIONTECH AG , Astellas Pharma Inc.
Inventor： Ugur Sahin , Christiane Stadler , Leyla Fischer , Arne Jendretzki , Özlem Türeci , Fabrice Le Gall , Maria Kreuzberg
CPC classification number: C07K16/2809 , A61P35/00 , C07K16/28 , C12N15/86 , A61K2039/505 , A61K2039/53 , C07K2317/31 , C07K2317/35 , C07K2317/55 , C07K2317/56 , C07K2317/622 , C07K2317/73 , C07K2317/92 , C07K2317/94
Abstract: The present invention provides binding agents comprising at least three binding domains, wherein a first binding domain binds to a T cell-specific antigen and a second binding domain and a third binding domain bind to a claudin, and methods of using these binding agents or nucleic acids encoding therefor for treating cancer.
-
Patent Agency Ranking
公开(公告)号：US11008550B2
公开(公告)日：2021-05-18
申请号：US16250366
申请日：2019-01-17
Applicant: BioNTech AG , TRON—Translationale Onkologie an der Universitatsmedizin der Johannes Gutenberg Universitat Mainz Gemeinnutzige GmbH
Inventor： Ugur Sahin , Marco Poleganov , Tim Beissert
Abstract: The present invention provides methods for de-differentiating somatic cells into stem-like cells without generating embryos or fetuses. More specifically, the present invention provides methods for effecting the de-differentiation of somatic cells to cells having stem cell characteristics, in particular pluripotency, by introducing RNA encoding factors inducing the de-differentiation of somatic cells into the somatic cells and culturing the somatic cells allowing the cells to de-differentiate.
-
公开(公告)号：US10717780B2
公开(公告)日：2020-07-21
申请号：US16117197
申请日：2018-08-30
Applicant: Biontech AG , Ganymed Pharmaceuticals GmbH , TRON—Translationale Onkologie an der Universitätsmedizin der Johannes Gutenberg-Universität Mainz gemeinnützige GmbH
Inventor： Ugur Sahin , Ozlem Türeci , Christiane Stadler , Julia Holland , Hayat Bähr-Mahmud , Tim Beissert , Laura Plum , Fabrice Le Gall , Arne Jendretzki , Markus Fiedler
Abstract: The present invention provides binding agents that contain n binding domain that is specific for CD3 allowing binding to T cells and a binding domain that is specific for a tumor-associated claudin molecule and methods of using these binding agents or nucleic acids encoding therefor for treating cancer.
-
公开(公告)号：US10550430B2
公开(公告)日：2020-02-04
申请号：US15031415
申请日：2014-10-24
Applicant: Biontech AG , TRON—Translationale Onkologie an der Universitätsmedizin der Johannes Gutenberg—Universität Mainz gemeinnutzige GmbH
Inventor： Ugur Sahin , Michael Schäfer , Marta Magdalena Faryna , Tana Omokoko , Lisa Hebich , Petra Simon , Annett Reichardt , Özlem Öz
IPC: C12Q1/68 , C07H21/04 , C12Q1/6881 , C12Q1/6876
Abstract: The present invention relates to a kit and a method for determining whether a subject shows an immune response against an antigen.
-
公开(公告)号：US10526387B2
公开(公告)日：2020-01-07
申请号：US15341528
申请日：2016-11-02
Applicant: BioNTech AG
Inventor： Thorsten Klamp , Ugur Sahin , Ozlem Tureci , Michael Koslowski , Thomas Hiller , Jens Schumacher
IPC: C07K14/47 , A61K39/00 , C07K14/005 , C12N7/00
Abstract: The present invention relates to tumor immunotherapy, in particular to tumor vaccination, using chimeric proteins comprising all or a portion of a hepatitis B virus core antigen protein and an amino acid sequence comprising an epitope derived from the extracellular portion of a tumor-associated antigen. In particular, the present invention provides virus-like particles comprising said chimeric proteins, which are useful for eliciting a humoral immune response in a subject against the tumor-associated antigen, in particular against cells carrying said tumor-associated antigen on their surface, wherein the tumor-associated antigen is a self-protein in said subject.
-
70.发明申请公开(公告)号：US20190309067A1
公开(公告)日：2019-10-10
申请号：US16335373
申请日：2017-09-20
Applicant: BIONTECH AG , Astellas Pharma Inc.
Inventor： Ugur Sahin , Christiane Stadler , Leyla Fischer , Arne Jendretzki , Özlem Türeci , Fabrice Le Gall , Maria Kreuzberg
Abstract: The present invention provides binding agents comprising at least three binding domains, wherein a first binding domain binds to a T cell-specific antigen and a second binding domain and a third binding domain bind to a claudin, and methods of using these binding agents or nucleic acids encoding therefor for treating cancer.
-
-
-
-
-
-
-
-
-
Search Results
81
records
(took 0.049 seconds)
